Precision Medicine in Phaeochromocytoma and Paraganglioma.
Publication Date
2021-11-22Journal Title
J Pers Med
ISSN
2075-4426
Publisher
MDPI AG
Volume
11
Issue
11
Language
en
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Winzeler, B., Challis, B. G., & Casey, R. T. (2021). Precision Medicine in Phaeochromocytoma and Paraganglioma.. J Pers Med, 11 (11) https://doi.org/10.3390/jpm11111239
Abstract
Precision medicine is a term used to describe medical care, which is specifically tailored to an individual patient or disease with the aim of ensuring the best clinical outcome whilst reducing the risk of adverse effects. Phaeochromocytoma and paraganglioma (PPGL) are rare neuroendocrine tumours with uncertain malignant potential. Over recent years, the molecular profiling of PPGLs has increased our understanding of the mechanisms that drive tumorigenesis. A high proportion of PPGLs are hereditary, with non-hereditary tumours commonly harbouring somatic mutations in known susceptibility genes. Through detailed interrogation of genotype-phenotype, correlations PPGLs can be classified into three different subgroups or clusters. Thus, PPGLs serve as an ideal paradigm for developing, testing and implementing precision medicine concepts in the clinic. In this review, we provide an overview of PPGLs and highlight how detailed molecular characterisation of these tumours provides current and future opportunities for precision oncology.
Keywords
personalized medicine, neuroendocrine tumours, phaeochromocytoma, paraganglioma, molecular clusters
Sponsorship
GIST SUPPORT UK (n/a)
Identifiers
External DOI: https://doi.org/10.3390/jpm11111239
This record's URL: https://www.repository.cam.ac.uk/handle/1810/331049
Rights
Licence:
https://creativecommons.org/licenses/by/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk